TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Bio Farma lands Rp 1.4t in vaccine export contracts for 2025
The state-owned pharmaceutical company, which ranks among the world’s largest vaccine manufacturers by production capacity, is scouting sites for a new factory to accommodate an ambitious expansion plan.
Change text size
Gift Premium Articles
to Anyone
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
A health worker shows a vial of polio vaccine on Jan. 16, 2024, before administering it to a child in Surabaya, East Java. (Antara/Didik Suhartono)
B
io Farma has secured Rp 1.4 trillion (US$88.9 million) in contracts to export vaccines, including shots for polio, diphtheria, tetanus and pertussis, starting next year.
The contracts, which cover half of the firm’s annual target of Rp 3 trillion, were obtained last month during the Developing Countries Vaccine Manufacturers Network (DCVMN) annual general meeting in São Paulo, Brazil.
The firm has not disclosed details of each contract but claimed that the margins for export shipments were typically “very high”.
According to State-Owned Enterprises (SOEs) Minister Erick Thohir, Bio Farma currently holds World Health Organization (WHO) licenses to produce 20 different vaccines.
With an annual production capacity of 3.1 billion doses, the company ranks among the world’s seven largest vaccine manufacturers.
“In 2023, Bio Farma’s export value reached Rp 2.9 trillion, with global distribution totaling 2 billion vaccine doses, reaching 700 million children across 153 countries. We plan to scale up production to increase output fivefold over the next 10 years across various types of vaccines,” Erick said during a press conference on Friday.
Bio Farma deputy president director Soleh Ayubi explained that expanding production capacity was not feasible within the company’s 130-year-old facility in Bandung, West Java, given land limitations and safety concerns over its proximity to residential areas.
